Rectal Neoplasms

• 

  Subject Areas on Research

  • 3-D comparative study of proton vs. x-ray radiation therapy for rectal cancer. 
  • A Phase I trial of preoperative eniluracil plus 5-fluorouracil and radiation for locally advanced or unresectable adenocarcinoma of the rectum and colon. 
  • A carcinoembryonic antigen (CEA) binding protein from ascites influences CEA uptake by macrophages. 
  • A case-controlled study of 18-fluorodeoxyglucose positron emission tomography in the detection of pelvic recurrence in previously irradiated rectal cancer patients. 
  • A phase I trial of recombinant human interleukin-1 beta alone and in combination with myelosuppressive doses of 5-fluorouracil in patients with gastrointestinal cancer. 
  • A phase I/II study of intraoperative radiotherapy in advanced unresectable or recurrent carcinoma of the rectum: a Radiation Therapy Oncology Group (RTOG) study. 
  • A pilot study of preoperative continuous infusion 5-fluorouracil, external microwave hyperthermia, and external beam radiotherapy for treatment of locally advanced, unresectable, or recurrent rectal cancer. 
  • A prospective pathologic analysis using whole-mount sections of rectal cancer following preoperative combined modality therapy: implications for sphincter preservation. 
  • A safety and survival analysis of neoadjuvant bevacizumab with standard chemoradiation in a phase I/II study compared with standard chemoradiation in locally advanced rectal cancer. 
  • A simple scoring system for risk-stratifying rectal cancer patients prior to radical resection. 
  • Abdominoperineal Resection for Rectal Cancer in the Twenty-First Century: Indications, Techniques, and Outcomes. 
  • Active specific immunotherapy of Dukes B2 and C colorectal carcinoma: comparison of two doses of the vaccine. 
  • Adequacy of 1-cm distal margin after restorative rectal cancer resection with sharp mesorectal excision and preoperative combined-modality therapy. 
  • Adequacy of distal resection margin following preoperative combined modality therapy for rectal cancer. 
  • Adjuvant Chemotherapy After Preoperative Chemoradiation Improves Survival in Patients With Locally Advanced Rectal Cancer. 
  • Adjuvant Chemotherapy Improves Survival Following Resection of Locally Advanced Rectal Cancer with Pathologic Complete Response. 
  • Adjuvant Chemotherapy for Stage II Rectal Cancer. 
  • Adjuvant postoperative radiation therapy for rectal adenocarcinoma. 
  • Adjuvant therapy in rectal cancer: analysis of stage, sex, and local control--final report of intergroup 0114. 
  • Advanced radiation therapy technologies in the treatment of rectal and anal cancer: intensity-modulated photon therapy and proton therapy. 
  • Advances in combined radiation therapy for the management of rectal cancer. 
  • Age and comorbidity association with survival outcomes in metastatic colorectal cancer: CALGB 80405 analysis. 
  • Anal-rectal cytology: correlation with human papillomavirus status and biopsy diagnoses in a population of HIV-positive patients. 
  • Analysis of surgical salvage after failure of primary therapy in rectal cancer: results from Intergroup Study 0114. 
  • Anorectal melanoma: clinical characteristics and results of surgical management in twenty-four patients. 
  • Anorectal melanoma: clinical characteristics and the role of abdominoperineal resection. 
  • Anterior rectal wall gastrointestinal stromal tumor presenting clinically as prostatic mass. 
  • Appropriate customization of radiation therapy for stage II and III rectal cancer: Executive summary of an ASTRO Clinical Practice Statement using the RAND/UCLA Appropriateness Method. 
  • Are metaplasias in colorectal adenomas truly metaplasias? 
  • Are there patients with stage I rectal carcinoma at risk for failure after abdominoperineal resection? 
  • Assessing the quality of colorectal cancer care: do we have appropriate quality measures? (A systematic review of literature). 
  • Assessing tumor perfusion and treatment response in rectal cancer with multisection CT: initial observations. 
  • Association Between Incomplete Neoadjuvant Radiotherapy and Survival for Patients With Locally Advanced Rectal Cancer. 
  • Association between neoadjuvant chemoradiation and survival for patients with locally advanced rectal cancer. 
  • Beam-orientation customization using an artificial neural network. 
  • Best Solutions for Perineal and Pressure Sore Reconstruction. 
  • Bevacizumab, oxaliplatin, and capecitabine with radiation therapy in rectal cancer: Phase I trial results. 
  • Beyond 5-fluorouracil: the emerging role of newer chemotherapeutics and targeted agents with radiation therapy. 
  • Cabozantinib with or without Panitumumab for RAS wild-type metastatic colorectal cancer: impact of MET amplification on clinical outcomes and circulating biomarkers. 
  • Cancer care quality measures: diagnosis and treatment of colorectal cancer. 
  • Cancer vaccines in colon and rectal cancer over the last decade: lessons learned and future directions. 
  • Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 18-2004. A 61-year-old man with rectal bleeding and a 2-cm mass in the rectum. 
  • Changes in tumor proliferation of rectal cancer induced by preoperative 5-fluorouracil and irradiation. 
  • Chemotherapeutic and biologic agents as radiosensitizers in rectal cancer. 
  • Circulating Tumor DNA Predicts Pathologic and Clinical Outcomes Following Neoadjuvant Chemoradiation and Surgery for Patients With Locally Advanced Rectal Cancer. 
  • Clear cell change in colonic tubular adenoma and corresponding colonic clear cell adenocarcinoma is associated with an altered mucin core protein profile. 
  • Clinical examination following preoperative chemoradiation for rectal cancer is not a reliable surrogate end point. 
  • Clinical practice variation in the management of diminutive colorectal polyps: results of a national survey of gastroenterologists. 
  • Cloacogenic carcinoma. 
  • Colitis cystica profunda: a pediatric case report. 
  • Colorectal cancer: adjuvant chemotherapy for rectal cancer-an unresolved issue. 
  • Combined modality therapy for rectal and colon cancer. 
  • Combined modality treatment for rectal cancer. 
  • Combined vascular endothelial growth factor-targeted therapy and radiotherapy for rectal cancer: theory and clinical practice. 
  • Combined-modality therapy for rectal cancer: future prospects. 
  • Commentary: rectal cancer an evolution of treatment. 
  • Complete pathologic response after chemoradiation for rectal cancer. 
  • Complete pathological response to bevacizumab and chemoradiation in advanced rectal cancer. 
  • Complete response to neoadjuvant chemoradiation for rectal cancer does not influence survival. 
  • Comprehensive genomic profiling in advanced/metastatic colorectal cancer: number needed to test and budget impact of expanded first line use. 
  • Computed tomography of the rectum. 
  • Current and future cancer staging after neoadjuvant treatment for solid tumors. 
  • Current immunotherapeutic strategies in colon cancer. 
  • Cyclooxygenase-2 (COX-2) levels before and after chemotherapy: a study in rectal cancer. 
  • Diagnosis and surgical treatment of colonic endometriosis. 
  • Dietary fat in relation to all-cause mortality and cancer progression and death among people with metastatic colorectal cancer: Data from CALGB 80405 (Alliance)/SWOG 80405. 
  • Dietary patterns, food groups, and rectal cancer risk in Whites and African-Americans. 
  • Differential CD146 expression on circulating versus tissue endothelial cells in rectal cancer patients: implications for circulating endothelial and progenitor cells as biomarkers for antiangiogenic therapy. 
  • Direct evidence that bevacizumab, an anti-VEGF antibody, up-regulates SDF1alpha, CXCR4, CXCL6, and neuropilin 1 in tumors from patients with rectal cancer. 
  • Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. 
  • Does Fragmentation of Care in Locally Advanced Rectal Cancer Increase Patient Mortality? 
  • Effect of preoperative irradiation on resectability of colorectal carcinomas. 
  • Effective pelvic symptom control using initial chemoradiation without colostomy in metastatic rectal cancer. 
  • Effective surgical adjuvant therapy for high-risk rectal carcinoma. 
  • Efficacy and safety of dilpacimab (ABT-165) versus bevacizumab plus FOLFIRI in metastatic colorectal cancer: a phase II study. 
  • Efficacy endpoints of radiation therapy group protocol 0247: a randomized, phase 2 study of neoadjuvant radiation therapy plus concurrent capecitabine and irinotecan or capecitabine and oxaliplatin for patients with locally advanced rectal cancer. 
  • Efficacy, safety, and biomarkers of neoadjuvant bevacizumab, radiation therapy, and fluorouracil in rectal cancer: a multidisciplinary phase II study. 
  • Elective clinical target volumes for conformal therapy in anorectal cancer: a radiation therapy oncology group consensus panel contouring atlas. 
  • Emerging Treatment Paradigms in Localized Rectal Cancer. 
  • Epigenetic markers in rectal cancer. 
  • Erythrocyte polyamine levels during intravenous feeding of patients with colorectal carcinoma. 
  • Evaluation of the risk factors associated with rectal neuroendocrine tumors: a big data analytic study from a health screening center. 
  • Evolution of minimally invasive surgery for rectal cancer: update from the national cancer database. 
  • Ex vivo evaluation of preoperatively treated rectal cancer specimens of patients undergoing radical resection. 
  • Expression of p27 in residual rectal cancer after preoperative chemoradiation predicts long-term outcome. 
  • Factors associated with use of preoperative chemoradiation therapy for rectal cancer in the Cancer Care Outcomes Research and Surveillance Consortium. 
  • Giant pelvic retroperitoneal leiomyoma arising from the rectal wall. 
  • Going beyond systemic fluoropyrimidines with radiation therapy for rectal cancer: what should be the priority? 
  • Growth kinetics of human colorectal carcinoma. 
  • Guest Editorial for: "Diagnostic Efficiency of Diffusion Sequences and a Clinical Nomogram for Detecting Lymph Node Metastases From Rectal Cancer". 
  • Guidelines 2000 for colon and rectal cancer surgery. 
  • Heterotopic ossification in rectal cancer: Rare finding with a novel proposed mechanism. 
  • High-dose human lymphoblastoid interferon in metastatic colorectal cancer: clinical results and modification of biological responses. 
  • High-dose, single-agent irinotecan as first-line therapy in the treatment of metastatic colorectal cancer. 
  • Hospital-level compliance with the commission on cancer's quality of care measures and the association with patient survival. 
  • How good is screening for colorectal cancer? 
  • Human colorectal carcinomas specifically accumulate Mr 42,000 ubiquitin-conjugated cytokeratin 8 fragments. 
  • Impact of T and N stage and treatment on survival and relapse in adjuvant rectal cancer: a pooled analysis. 
  • Impact of body mass index on outcomes and treatment-related toxicity in patients with stage II and III rectal cancer: findings from Intergroup Trial 0114. 
  • Impact of hospital procedure volume on surgical operation and long-term outcomes in high-risk curatively resected rectal cancer: findings from the Intergroup 0114 Study. 
  • Impact of number of nodes retrieved on outcome in patients with rectal cancer. 
  • Impact of time duration after neoadjuvant therapy to surgery on response and outcome in rectal cancer patients. 
  • Importance of the Circumferential Resection Margin. 
  • Improved overall survival among responders to preoperative chemoradiation for locally advanced rectal cancer. 
  • In Reply to Gerard. 
  • Increased content of chondroitin sulfate proteoglycan in human colorectal carcinoma metastases compared with the primary tumor as determined by an anti-chondroitin-sulfate monoclonal antibody. 
  • Increased toxicity with gefitinib, capecitabine, and radiation therapy in pancreatic and rectal cancer: phase I trial results. 
  • Induction chemotherapy followed by chemoradiotherapy versus chemoradiotherapy alone as neoadjuvant treatment for locally recurrent rectal cancer: study protocol of a multicentre, open-label, parallel-arms, randomized controlled study (PelvEx II). 
  • Insurance Status, Not Race, is Associated With Use of Minimally Invasive Surgical Approach for Rectal Cancer. 
  • Intensity-Modulated Radiation Therapy Is Not Associated with Perioperative or Survival Benefit over 3D-Conformal Radiotherapy for Rectal Cancer. 
  • Intraoperative electron beam radiation therapy for primary locally advanced rectal and rectosigmoid carcinoma. 
  • Intraoperative electron beam radiation therapy for recurrent locally advanced rectal or rectosigmoid carcinoma. 
  • Intraoperative interstitial microwave-induced hyperthermia and brachytherapy. 
  • Intraoperative radiation therapy for locally advanced recurrent rectal or rectosigmoid cancer. 
  • Intraoperative radiation therapy for locally advanced recurrent rectal or rectosigmoid cancer. 
  • Intraoperative radiation therapy. 
  • Intraoperative radiation therapy. 
  • Introduction: current controversies in rectal cancer. 
  • Is follow-up CT imaging of the chest and abdomen necessary after preoperative neoadjuvant therapy in rectal cancer patients without evidence of metastatic disease at diagnosis? 
  • Is intraoperative lymph node mapping and sentinel lymph node biopsy for colorectal carcinoma necessary? 
  • Is radiation therapy required for patients with intermediate-risk rectal cancer? 
  • Laparoscopic intestinal stomas. 
  • Laparoscopic versus open low anterior resection for rectal cancer: results from the national cancer data base. 
  • Late complications of postoperative radiation therapy for cancer of the rectum and rectosigmoid. 
  • Local excision of distal rectal cancer: an update of cancer and leukemia group B 8984. 
  • Local excision of rectal cancer revisited: ACOSOG protocol Z6041. 
  • Local excision results in comparable survival to radical resection for early-stage rectal carcinoid. 
  • Local recurrence of rectal cancer: evaluation with F-18 fluorodeoxyglucose PET imaging. 
  • Local therapy for rectal cancer. 
  • Locally unresectable rectal cancer. American College of Radiology. ACR Appropriateness Criteria. 
  • Long-term Clinical Outcomes of Nonoperative Management With Chemoradiotherapy for Locally Advanced Rectal Cancer in the Veterans Health Administration. 
  • Long-term follow-up of patients with rectal cancer managed by local excision with and without adjuvant irradiation. 
  • Loss of KAI1 expression in the progression of colorectal cancer. 
  • Lymphoscintigraphy for malignant melanoma. Surgical considerations. 
  • MRI Evaluation of the Response of Rectal Cancer to Neoadjuvant Chemoradiation Therapy. 
  • Malignant melanoma of the mucous membranes: a review of 119 cases. 
  • Management of Locoregional Rectal Cancer. 
  • Management of resectable rectal cancer. American College of Radiology. ACR Appropriateness Criteria. 
  • Management strategies for patients with advanced rectal cancer and liver metastases using modified Delphi methodology: results from the PelvEx Collaborative. 
  • Microsatellite instability is frequently observed in rectal cancer and influenced by neoadjuvant chemoradiation. 
  • Minimally Invasive Versus Open Low Anterior Resection: Equivalent Survival in a National Analysis of 14,033 Patients With Rectal Cancer. 
  • Multidisciplinary management of locally advanced rectal cancer: neoadjuvant approaches. 
  • Multimodality management of locally advanced rectal cancer. 
  • NCCN Clinical Practice Guidelines in Oncology: rectal cancer. 
  • NCCN Guidelines Insights: Rectal Cancer, Version 6.2020. 
  • Neoadjuvant chemoradiation followed by transanal local excision for T2 rectal cancer confers equivalent survival benefit as traditional transabdominal resection. 
  • Neoadjuvant chemoradiation for distal rectal cancer: 5-year updated results of a randomized phase 2 study of neoadjuvant combined modality chemoradiation for distal rectal cancer. 
  • Neoadjuvant chemoradiation for rectal cancer reduces lymph node harvest in proctectomy specimens. 
  • Neoadjuvant chemoradiation for rectal cancer: analysis of clinical outcomes from a 13-year institutional experience. 
  • Neoadjuvant long-course chemoradiation remains strongly favored over short-course radiotherapy by radiation oncologists in the United States. 
  • New approaches to assessing and treating early-stage colon and rectal cancer: summary statement from 2007 Santa Monica Conference. 
  • Nonoperative management of rectal cancer. 
  • Nonoperative management of rectal cancer: current perspectives. 
  • Optimal Timing to Surgery after Neoadjuvant Chemoradiotherapy for Locally Advanced Rectal Cancer. 
  • Organ preservation in anal and rectal cancers. 
  • Palliative treatment of rectal cancer: is radiotherapy alone a good option? 
  • Pathological downstaging does not guide the need for IORT in primary locally advanced rectal cancer. 
  • Patterns of failure following local excision and local excision and postoperative radiation therapy for invasive rectal adenocarcinoma. 
  • Patterns of failure in patients with early onset (synchronous) resectable liver metastases from rectal cancer. 
  • Patterns of morphologic alteration in residual rectal carcinoma following preoperative chemoradiation and their association with long-term outcome. 
  • Patterns of residual disease after preoperative chemoradiation in ultrasound T3 rectal carcinoma. 
  • Phase I Study of Lenvatinib and Capecitabine with External Radiation Therapy in Locally Advanced Rectal Adenocarcinoma. 
  • Phase I and II studies of the combination of recombinant human interferon-gamma and 5-fluorouracil in patients with advanced colorectal carcinoma. 
  • Phase I study of preoperative oral uracil and tegafur plus leucovorin and radiation therapy in rectal cancer. 
  • Phase I/II study of preoperative oxaliplatin, fluorouracil, and external-beam radiation therapy in patients with locally advanced rectal cancer: Cancer and Leukemia Group B 89901. 
  • Phase II study of fludarabine phosphate in patients with advanced colorectal carcinoma. 
  • Phase II trial of lymphoblastoid interferon in metastatic colon carcinoma. 
  • Plasma soluble VEGFR-1 is a potential dual biomarker of response and toxicity for bevacizumab with chemoradiation in locally advanced rectal cancer. 
  • Pre-Treatment Staging Imaging in Rectal Cancer: Results From the Quality Oncology Practice Initiative. 
  • Predicting outcomes of pelvic exenteration using machine learning. 
  • Predictive value of initial imaging and staging with long-term outcomes in young adults diagnosed with colorectal cancer. 
  • Predictors of Long-Term Quality of Life for Survivors of Stage II/III Rectal Cancer in the Cancer Care Outcomes Research and Surveillance Consortium. 
  • Preliminary analysis of a randomized comparison of 5-fluorouracil versus 5-fluorouracil and high-dose continuous-infusion folinic acid in disseminated colorectal cancer. 
  • Preoperative and postoperative CT staging of rectosigmoid carcinoma. 
  • Preoperative chemotherapy and radiation therapy for locally advanced primary and recurrent rectal carcinoma. A report of surgical morbidity. 
  • Preoperative concurrent chemotherapy and radiotherapy in rectal cancer patients. 
  • Preoperative infusional chemoradiation and surgery with or without an electron beam intraoperative boost for advanced primary rectal cancer. 
  • Preoperative infusional chemoradiation therapy for stage T3 rectal cancer. 
  • Preoperative irradiation for tethered rectal carcinoma. 
  • Preoperative radiation and chemotherapy in the treatment of adenocarcinoma of the rectum. 
  • Preoperative radiotherapy for rectal cancer: benefits and controversies. 
  • Primary rectal adenocarcinoma presenting as a giant perianal mass mimicking giant condyloma of Buschke-Lowenstein. 
  • Prognostic factors in stage T3N0 rectal cancer: do all patients require postoperative pelvic irradiation and chemotherapy? 
  • Prognostic impact of micrometastases in colon cancer: interim results of a prospective multicenter trial. 
  • Prognostic implications of response to preoperative infusional chemoradiation in locally advanced rectal cancer. 
  • Prognostic significance of depth of gross or microscopic perirectal fat invasion in T3 N0 M0 rectal cancers following sharp mesorectal excision and no adjuvant therapy. 
  • Proliferating cell nuclear antigen and mitotic activity in rectal cancer: predictor of response to preoperative irradiation. 
  • Prospective phase I trial of conservative management of low rectal lesions. 
  • Prospective randomized comparison of fluorouracil versus fluorouracil and high-dose continuous infusion leucovorin calcium for the treatment of advanced measurable colorectal cancer in patients previously unexposed to chemotherapy. 
  • Prospective trial of preoperative concomitant boost radiotherapy with continuous infusion 5-fluorouracil for locally advanced rectal cancer. 
  • Prostatic carcinosarcoma 15 years after combined external beam radiation and brachytherapy for prostatic adenocarcinoma: a case report. 
  • Pulmonary fibrosis, carcinoma, and ferruginous body counts in amosite asbestos workers. A study of six cases. 
  • Radiation Therapy Oncology Group 0247: a randomized Phase II study of neoadjuvant capecitabine and irinotecan or capecitabine and oxaliplatin with concurrent radiotherapy for patients with locally advanced rectal cancer. 
  • Radiation Therapy for Rectal Cancer: Executive Summary of an ASTRO Clinical Practice Guideline. 
  • Radiation therapy for rectosigmoid and rectal cancer: results of the 1992-1994 Patterns of Care process survey. 
  • Radiation therapy in anal and rectal cancer. 
  • Radiation therapy in stage II and III rectal cancer. 
  • Radiation therapy in the management of rectal cancer. 
  • Radical radiotherapy versus abdominoperineal resection. 
  • Randomized phase II study of neoadjuvant combined-modality chemoradiation for distal rectal cancer: Radiation Therapy Oncology Group Trial 0012. 
  • Randomized study of continuous infusion fluorouracil versus fluorouracil plus cisplatin in patients with metastatic colorectal cancer. 
  • Rate of pathologic complete response with increased interval between preoperative combined modality therapy and rectal cancer resection. 
  • Rectal Cancer, Version 2.2015. 
  • Rectal Cancer, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology. 
  • Rectal Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology. 
  • Rectal cancer. 
  • Rectal cancer: presentation with metastatic and locally advanced disease. American College of Radiology. ACR Appropriateness Criteria. 
  • Rectal cancer: the influence of tumor proliferation on response to preoperative irradiation. 
  • Rectal cancer: the sphincter-sparing approach. 
  • Rectothecal Fistula Secondary to a Tailgut Cyst With Malignant Transformation: An Abnormal Connection and Unusual Pathology. 
  • Relationship between surgeon caseload and sphincter preservation in patients with rectal cancer. 
  • Resected irradiated rectal cancers: Are twelve lymph nodes really necessary in the era of neoadjuvant therapy? 
  • Residual mesorectal lymph node involvement following neoadjuvant combined-modality therapy: rationale for radical resection? 
  • Response to Letter: Comment on "Insurance Status, Not Race Is Associated With Use of Minimally Invasive Surgical Approach for Rectal Cancer". 
  • Response to Mroczkowski. 
  • Response: "Recognizing Implicit Bias, Not Proteomics, Is the Next Step in Mitigating Disparities in Surgical Care". 
  • Risk of colorectal neoplasm in patients with acromegaly and its relationship with serum growth hormone levels. 
  • Robotic Low Anterior Resection for Rectal Cancer: A National Perspective on Short-term Oncologic Outcomes. 
  • Safety and tolerability of veliparib combined with capecitabine plus radiotherapy in patients with locally advanced rectal cancer: a phase 1b study. 
  • Selection factors for local excision or abdominoperineal resection of early stage rectal cancer. 
  • Sensitivity of the Hemoccult II slide test in detecting colonic neoplasms. 
  • Sequential preoperative fluorodeoxyglucose-positron emission tomography assessment of response to preoperative chemoradiation: a means for determining longterm outcomes of rectal cancer. 
  • Short-course versus long-course chemoradiation in rectal cancer--time to change strategies? 
  • Sialyl-dimeric Lewis-X antigen expressed on mucin-like glycoproteins in colorectal cancer metastases. 
  • Significance of a fall in serum CEA concentration in patients treated with cytotoxic chemotherapy for disseminated colorectal cancer. 
  • Simultaneous pelvic exenteration and liver resection for primary rectal cancer with synchronous liver metastases: results from the PelvEx Collaborative. 
  • Simultaneous resection for rectal cancer with synchronous liver metastasis is a safe procedure. 
  • Simultaneous thigh muscle metastasis from lung cancer and Escherichia coli gas producing myonecrosis. 
  • Soft tissue complication rates after low dose rate brachytherapy using customized perineal templates. 
  • Sphincter preservation in rectal cancer. 
  • Sphincter preservation in rectal cancer. Local excision followed by postoperative radiation therapy. 
  • Sphincter-sparing surgery in patients with low-lying rectal cancer: techniques, oncologic outcomes, and functional results. 
  • Sphincter-sparing treatment for distal rectal adenocarcinoma. 
  • Suppository administration of chemotherapeutic drugs with concomitant radiation for rectal cancer. 
  • Surrogate markers for antiangiogenic therapy and dose-limiting toxicities for bevacizumab with radiation and chemotherapy: continued experience of a phase I trial in rectal cancer patients. 
  • Survival Advantage With Adjuvant Chemotherapy for Locoregionally Advanced Rectal Cancer: A Veterans Health Administration Analysis. 
  • Survival after hepatic resection for metastatic colorectal cancer: trends in outcomes for 1,600 patients during two decades at a single institution. 
  • Survival in Young-Onset Metastatic Colorectal Cancer: Findings From Cancer and Leukemia Group B (Alliance)/SWOG 80405. 
  • Synchronous primary perianal Paget's disease and rectal adenocarcinoma: report of a hitherto undescribed phenomenon. 
  • T4 rectal cancer treated with preoperative chemoradiation to the posterior pelvis followed by multivisceral resection: patterns of failure and limitations of treatment. 
  • TNF rs1799964 as a Predictive Factor of Acute Toxicities in Chinese Rectal Cancer Patients Treated With Chemoradiotherapy. 
  • Targeted therapy in rectal cancer. 
  • Technical advances in the treatment of patients with rectal cancer. 
  • Template for reporting results of biomarker testing of specimens from patients with carcinoma of the colon and rectum. 
  • The Kraske procedure: a critical analysis of a surgical approach for mid-rectal lesions. 
  • The Pedunculated Pretender: A Case of Invasive Anorectal Mucosal Melanoma. 
  • The Selective Use of Radiation Therapy in Rectal Cancer Patients. 
  • The Symptom Experience in Rectal Cancer Survivors. 
  • The Use of Re-irradiation in Locally Recurrent, Non-metastatic Rectal Cancer. 
  • The anatomical distribution of colorectal polyps at colonoscopy. 
  • The epidemiology of tea consumption and colorectal cancer incidence. 
  • The impact of 5-fluorouracil and intraoperative electron beam radiation therapy on the outcome of patients with locally advanced primary rectal and rectosigmoid cancer. 
  • The impact of the COVID-19 pandemic on the Management of Locally Advanced Primary/Recurrent Rectal Cancer. 
  • The natural history of colorectal carcinoma in adolescents. 
  • The pelvis after surgery for rectal carcinoma: serial CT observations with emphasis on nonneoplastic features. 
  • The prognostic significance of stapler doughnuts' examination at low anterior resection for rectal cancer. 
  • The relationship of collagenolytic activity to stage of human colorectal carcinoma. 
  • Tolerability of combined modality therapy for rectal cancer in elderly patients aged 75 years and older. 
  • Total neoadjuvant therapy for rectal cancer: An emerging option. 
  • Transpelvic rectus abdominis flap reconstruction of defects following abdominal-perineal resection. 
  • Treatment of Metastatic Colorectal Cancer: ASCO Guideline. 
  • Treatment systems guidelines for primary rectal cancer from the 1996 Patterns of Care Study. 
  • Tucatinib plus trastuzumab for chemotherapy-refractory, HER2-positive, RAS wild-type unresectable or metastatic colorectal cancer (MOUNTAINEER): a multicentre, open-label, phase 2 study. 
  • Tumor downstaging and sphincter preservation with preoperative chemoradiation in locally advanced rectal cancer: the M. D. Anderson Cancer Center experience. 
  • Tumor proliferation in rectal cancer following preoperative irradiation. 
  • Ulex europeus agglutinin I-reactive high molecular weight glycoproteins of adenocarcinoma of distal colon and rectum and their possible relationship with metastatic potential. 
  • Unnecessary histologic examination of stapler doughnuts at low anterior resection for rectal cancer: Is it just a blame game? 
  • Update on treatment advances in combined-modality therapy for anal and rectal carcinomas. 
  • Urinary cyclic adenosine monophosphate as an aid in the diagnosis of hyperparathyroidism. 
  • V-Y fasciocutaneous flap closure technique is a safe and efficacious alternative to primary closure of the perineal wound following abdominoperineal resection. 
  • Validation of the English translation of the low anterior resection syndrome score. 
  • [Variation of mortality risk among cancer patients and individualized therapy]. 
  • ctDNA applications and integration in colorectal cancer: an NCI Colon and Rectal-Anal Task Forces whitepaper. 
• 

  Keywords of People

  • Jowell, Paul Simon, Professor of Medicine, Medicine, Gastroenterology